The effectiveness of PCSK9 mAbs in reducing ASCVD events is also found to be most pronounced in patients with high Lp(a) and that the reduction in Lp(a) could also partly mediate the benefit (O’Donoghue et al., 2019; Bittner et al., 2020). The gene discussed is LPA; the disease is atherosclerosis.